Post-approval studies (Phase 4)Study completedNCT00154323
What this trial is testing
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.
Who this might be right for
Bipolar Disorder
Novartis 55